Increased burden of ultra-rare structural variants localizing to boundaries of topologically associated domains in schizophrenia by Halvorsen, Matthew et al.
Increased burden of ultra-rare structural variants localizing to
boundaries of topologically associated domains in schizophrenia
Downloaded from: https://research.chalmers.se, 2020-07-11 06:25 UTC
Citation for the original published paper (version of record):
Halvorsen, M., Huh, R., Oskolkov, N. et al (2020)
Increased burden of ultra-rare structural variants localizing to boundaries of topologically
associated domains in schizophrenia
Nature Communications, 11(1): 1842-
http://dx.doi.org/10.1038/s41467-020-15707-w
N.B. When citing this work, cite the original published paper.
research.chalmers.se offers the possibility of retrieving research publications produced at Chalmers University of Technology.
It covers all kind of research output: articles, dissertations, conference papers, reports etc. since 2004.
research.chalmers.se is administrated and maintained by Chalmers Library
(article starts on next page)
ARTICLE
Increased burden of ultra-rare structural variants
localizing to boundaries of topologically associated
domains in schizophrenia
Matthew Halvorsen1,10, Ruth Huh2,10, Nikolay Oskolkov 3,10, Jia Wen 1,10, Sergiu Netotea4,
Paola Giusti-Rodriguez 1, Robert Karlsson 5, Julien Bryois5, Björn Nystedt 6, Adam Ameur 7,
Anna K. Kähler5, NaEshia Ancalade1, Martilias Farrell 1, James J. Crowley1,8,9, Yun Li1,2,
Patrik K. E. Magnusson 5, Ulf Gyllensten7, Christina M. Hultman5, Patrick F. Sullivan1,5,8✉ &
Jin P. Szatkiewicz 1,8✉
Despite considerable progress in schizophrenia genetics, most findings have been for large
rare structural variants and common variants in well-imputed regions with few genes
implicated from exome sequencing. Whole genome sequencing (WGS) can potentially
provide a more complete enumeration of etiological genetic variation apart from the exome
and regions of high linkage disequilibrium. We analyze high-coverage WGS data from 1162
Swedish schizophrenia cases and 936 ancestry-matched population controls. Our main
objective is to evaluate the contribution to schizophrenia etiology from a variety of genetic
variants accessible to WGS but not by previous technologies. Our results suggest that ultra-
rare structural variants that affect the boundaries of topologically associated domains (TADs)
increase risk for schizophrenia. Alterations in TAD boundaries may lead to dysregulation of
gene expression. Future mechanistic studies will be needed to determine the precise func-
tional effects of these variants on biology.
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S ince the first major study over 70 years ago
1, twin, family,
and adoption studies have strongly and consistently sup-
ported the existence of a genetic basis for schizophrenia2–4.
Its inheritance is complex with both genetic and non-genetic
contributions indicated by estimates of pedigree-heritability
(60–65%)3,4 and twin-heritability (81%)2 that are well under
100%. Although these genetic epidemiological results were fairly
consistent, their validity was dependent on multiple assumptions
and contained specific information about genetic architecture.
In the past decade, genome-wide association (GWA) studies
that genotyped hundreds of thousands of single-nucleotide
polymorphisms (SNPs) in tens of thousands of cases and con-
trols have directly evaluated the common-variant SNP-herit-
ability of schizophrenia5–7. In the most recent study of
40,675 schizophrenia cases and 64,643 controls, the SNP-
heritability of schizophrenia was 24.4% (SE 0.0091, liability
scale), and 145 significant loci were identified6. SNP array data
can also be used to assess rare copy number variants (CNVs). In
the largest study to date of 21,094 cases and 20,227 controls8,
eight CNVs reached genome-wide significance: CNV deletions at
1q21.1, 2p16.3 (NRXN1), 3q29, 15q13.3, and 16p11.2 (distal) and
22q11.2 plus CNV duplications at 7q11.23 and 16p11.2 (prox-
imal). These events were uncommon and any one of these eight
CNVs were present in 1.42% of cases and 0.15% of controls.
There is evidence that rare coding single-nucleotide variants
(SNVs) and insertion–deletions (indels) contribute to risk in a
low percentage of cases although few genes have been implicated
from exome sequencing9–11.
Thus, after a decade of increasingly larger studies, the dis-
covered genetic variants that confer risk for schizophrenia are
primarily common variants with subtle effects on risk6,7,9,10. The
interpretation of common variant findings is markedly improved
via the addition of functional genomic data from brain7,12,13;
nonetheless, there remains a gap between the pedigree- and twin-
heritability estimates for schizophrenia and its SNP-heritability.
Some argue that this gap is irrelevant as these different types of
heritability are incompatible and as biological insights have
always been the core goal of GWA for schizophrenia rather than
accounting for twin/pedigree heritability. It is also possible that
the heritability gap is informative, that SNP array and WES are
missing etiologically important genetic variation. GWA geno-
typing directly captures 500K-1M SNPs followed by imputation
to indirectly assess 7–10M variants. This process is imprecise as
some regions of the genome are not well covered, and some non-
SNP types of genetic variation are missed. WES provides data on
the protein-coding fraction of the genome (~3%) and will miss
many regulatory features.
By evaluating high-coverage WGS data on 21,620 individuals
in the TOPMed study, Wainschtein et al.14 reported recovery of
nearly all of the pedigree heritability for height and body mass
index. The missing heritability was found to reside in rarer
genetic variation (minor allele frequency (MAF) 0.0001–0.1) in
regions of relatively low linkage disequilibrium (LD) and often
outside of protein-coding portions of the genome. The funda-
mental reason for the missing heritability of height and body
mass may merely be technical: the least expensive technologies
only partly assess the genome with inexpensive SNP arrays cap-
turing common variants in high LD regions and WES capturing
much of the known protein-coding genome. The Wainschtein
et al. finding is consistent with prior observations that rarer and
evolutionarily younger SNPs have higher SNP-heritability for
multiple complex traits15.
To capture genetic variation as comprehensively as possible,
WGS is required. WGS provides nucleotide-level resolution
throughout the accessible genome along with detection of most
structural variants (SVs). Many types of genetic variation are
discoverable by WGS without regard to local LD, and these
include SNVs and indels in low LD regions, uncommon or rare
regulatory variants, rare SVs missed by SNP arrays and WES due
to small size or complexity, and common SVs missed by SNP
arrays. The NHLBI TOPMed Program recently published high-
coverage (30×) WGS data of 53,831 diverse individuals that
included ~381M SNVs and ~29M indels16. TOPMed WGS
identified 16% more variants than low-coverage WGS (6×), with
essentially all new variants being rare (MAF < 0.005); and 17%
more coding variants than both low-coverage WGS and WES
(30×). The distribution of variant sites in TOPMed WGS revealed
that the vast majority of human genetic variation is rare and
noncoding. There are a few published WGS studies of schizo-
phrenia (Supplementary Table 1). Of these studies, many
employed family-based designs and the largest case–control WGS
study had 321 schizophrenia cases and 148 controls.
In this study, we analyze high-coverage WGS from 1162 schi-
zophrenia cases and 936 ancestry-matched population controls.
WGS data are generated using identical protocols at the same
facility and all WGS data are jointly processed and analyzed. The
schizophrenia cases also have SNP array17,18 and exome
sequencing data9,10 which is compared to WGS to assess data
quality. Our main objective is to evaluate the contribution to
schizophrenia etiology from variants that are revealed by WGS
but not by GWA and WES. To quantify phenotypic variance
explained by rare variants, we estimate heritability using WGS.
To identify the role of noncoding variants, we focus on empiri-
cally determined maps of sequence constraints19,20 and functional
genomic annotations generated in human brain12,13. We parti-
cularly focus on ultra-rare variants as this frequency class has a
notable impact on schizophrenia risk in WES and CNV
studies8,10. We replicate key prior reported excess in schizo-
phrenia of loss-of-function (LOF) ultra-rare sequence variants in
LOF-intolerant genes. We find an increased burden in schizo-
phrenia of ultra-rare SVs that affect the boundaries of topologi-
cally associated domains.
Results
Overview. Figure 1 gives an overview of the study. Our workflow
was designed to evaluate the contribution of directly genotyped
genetic variation across the allelic spectrum and evaluate genetic
variation missed by prior approaches.
Study samples and sequencing. Following quality control, we
analyzed WGS on 1162 schizophrenia cases and 936 ancestry-
matched population controls from Sweden (total 2098 subjects).
Cases were selected to have typical Swedish ancestry, unequivocal
schizophrenia case status, and without a known pathogenic CNV
(e.g., 22q11 deletion). Controls were group matched to cases by
ancestry. The median WGS coverage per sample was 36.62 reads
per base (Supplementary Fig. 1). For each group, we constructed a
curve for mean fraction of bases covered deeper than a specified
threshold as a function of depth of coverage. The shapes of the
mean curves were similar between cases and controls (Supple-
mentary Fig. 2). Principal components analysis confirmed the
relative homogeneity of the sample (Supplementary Fig. 3).
We took multiple steps to minimize chances of spurious
associations with schizophrenia: (1) WGS for all subjects was
performed at the same facility using identical procedures; (2) all
WGS data were jointly processed; (3) variant calling was conducted
jointly for all subjects; (4) all subjects were ethnic Swedes of similar
empirical ancestry (Supplementary Fig. 3); and (5) in association
analyses, we controlled for empirically determined potential
confounders to mitigate impact on spurious association signals
(Methods). As discussed more fully below, we did not find evidence
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of inflation (e.g., for common variant case-controls tests, λGC was
1.03 and LD score regression intercept was 0.997 (SE= 0.0065),
which are inconsistent with systematic biases).
WGS variant identification. SNV/indels: We detected 33,746,530
SNVs and 4,551,507 indels across the autosomes of the 2098 cases
and controls. Individual subjects had a mean of 2,358,544 SNVs
(range: 2,063,297–2,513,607), and 383,929 indels (range
329,678–409,893; mean insertion size 3.09 bp and mean deletion
size 3.59 bp). Of the full set of unique SNVs and indels detected in
the WGS data, 45.43% of SNVs and 37.03% of indels were
detected in only one individual as heterozygotes (singletons).
These data included many variants not found in imputation
reference panels. For example, when requiring exact match for
chromosome, position, reference, and alternative allele,
15,688,760 SNVs are not in Haplotype Reference Consortium
(HRC r1.1) reference panel21 (stratified by MAF: 286,599 MAF >
0.05, 163,346 MAF 0.005–0.05, 15,238,815 MAF < 0.005);
21,574,998 SNVs are not in 1000 Genomes Project phase 3
(1000GP p3v5) reference panel22 (61,993 MAF > 0.05, 309,989
MAF 0.005–0.05, 21,203,016 MAF < 0.005), and 12,341,197
SNVs are not in TOPMed16 Freeze 3a (stratified by MAF: 28,179
MAF > 0.05, 29,233 MAF 0.005–0.05, 12,283,785 MAF < 0.005).
We also called 57,785 SNVs and 8270 indels on chrX, and
subjects had a mean of 6084 SNVs (range 5035–7183) and 1753
indels (range 1334–2091).
To evaluate the capacity of WGS to detect SNVs or indels, we
compared our WGS data to independent exome sequencing data
on 1154 of the 1162 schizophrenia cases10. We estimated
genotype accuracy by calculating the concordance rate between
genotypes from WGS and WES10 for all autosomes. For SNVs,
genotype accuracy was 0.9999, 0.999, and 0.997 for homozygous
reference, heterozygous, and homozygous non-reference geno-
types (Supplementary Table 2a). For indels, genotype accuracy
was 0.998, 0.984, and 0.984 for homozygous reference, hetero-
zygous, and homozygous non-reference genotypes (Table S2a).
When stratified by MAF, genotype accuracy estimates were
consistent across common, low-frequency, rare, and ultra-rare
variants, and similar to the overall genotype accuracy (Supple-
mentary Table 2b–e).
SVs: We detected 17,895 deletion (DEL) sites, 4129 tandem
duplication (DUP) sites, 4458 inversion (INV) sites, and 27,808
mobile element insertions sites (MEI, including 23,432 ALU, 1429
SVA, and 2956 LINE1). The sizes of DEL, DUP, and INV ranged
from 500 bp to 1Mb, with median sizes of 2592 bp for DEL, 7179
bp for DUP, and 3265 bp for INV (Supplementary Fig. 4). The
sizes of MEI ranged from 15–6019 bp, with a median size of 279 bp
for ALU, 1162 bp for SVA, and 1780 bp for LINE1 (Supplementary
Fig. 5). For any non-reference genotype, subjects carried a mean of
1241 DEL (range 657–1357), 183 DUP (range 157–209), 373 INV
(range 321–878), 2663 ALU (range 2077–3439), 82 SVA (range
56–107), and 249 LINE1 (range 196–302).
To evaluate the capacity of WGS to detect SVs, we compared
WGS data to prior copy number variant data from GWA SNP
array18 and WES23 on 1085 of the 1162 schizophrenia cases. First,
INV, MEI, and common SVs are largely inaccessible to SNP
arrays18 and WES studies23. Second, prior GWA SNP array
studies were limited to deletions and duplications >100 kb;
however, >95% of DEL and >77% DUP detected from WGS were
<20 kb. Consequently, SNP arrays found only 3.5% of DEL
variants and 17.7% of DUP variants found by WGS (requiring
50% reciprocal overlap). Third, when restricted to exons, WES
found only 13.7% of exonic DEL and 35.6% of exonic DUP
variants found by WGS (based on 50% reciprocal overlap).
Finally, for DEL and DUP variants that are comparable between
technologies, we computed concordance rates between WGS and
SNP array or WES (Supplementary Table 3). When compared to
SNP arrays, we estimated that the concordance rate was 0.992 for
DEL and 0.965 for DUP. When compared to WES, we estimated
that the concordance rate was 0.987 for DEL and 0.967 for DUP.
Repeat expansions: WGS can detect pathogenic disease-
associated repeat expansions (e.g., the HTT CAG repeat that
causes Huntington’s disease), which are inaccessible to SNP arrays.
We screened our samples for repeat expansions in 16 genes that are
established causes of disease, and found that 16 cases and 7 controls
had modest repeat expansions just within the predicted pathogenic
range (Supplementary Table 4). Because no case or control had a
register diagnosis consistent with these generally highly penetrant
disorders, we assumed these were false positives or the modest
repeat expansions were not long enough to cause disease.
Burden analysis of ultra-rare SNV/indels. Consistent with recent
studies10, we focused on ultra-rare sequence variants (URVs)
including ultra-rare SNVs and indels. We defined URVs as found
once in the WGS case/control cohort and absent from indepen-
dent population cohorts (i.e., gnomAD r2.0.2 allele count= 0 and
non-psychiatric subset of ExAC r0.3 allele count= 0)24,25. From
theory26 and our calculations (Supplementary Fig. 6), power is low
for single-variant analysis for MAF < 0.01. Collapsing methods are
Fig. 1 Overview of WGS analysis.WGS data were generated using identical
protocols at the same facility and all WGS data were jointly processed and
analyzed. The schizophrenia cases also had GWA SNP array and exome-
sequencing data for comparison for the purpose of quality assessment. We
started with 1165 schizophrenia cases and 942 ancestry-matched population
controls. After QC, 1162 cases and 936 controls remained. Variant
annotation focused on empirically determined annotation methods.
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key approaches for rare variants and can enhance power by
accumulating information across different rare variants that
impact a gene/locus or a set of genes/loci27. We used burden
testing as the primary analytical tool to contrast cases and controls
for total event counts in genomic loci of interest. Burden testing is
appropriate when most variants across a set of genetic loci impact
phenotype in the same direction and with similar magnitude27. We
estimated statistical power for burden tests and found that we had
≥80% power to detect association of URVs when the aggregated
minor allele count (MAC) was 20 (i.e., aggregated MAF= 0.01)
and the genotypic relative risk was ≥4.9 (assuming a type I error
level of 1 × 10−5). As a final step in quality control and following
an approach previously established in the full Swedish sample10,
we pruned samples that had an outlier total URV count mostly
because of relatively higher ancestry heterogeneity10 (Methods,
Supplementary Figs. 7 and 8). We conducted burden analyses of
URVs in 1104 cases and 921 controls (mean URV counts in cases
vs controls: 4262 vs 4249, P= 0.4225, Supplementary Fig. 7). The
total number of qualifying URVs in these samples was 8,073,782,
of which 7,991,557 (98.9%) were noncoding. Full results are listed
in Supplementary Table 5 and summarized below. For multiple-
testing adjustment, we applied the Benjamini and Hochberg false
discovery rate (BH-FDR) method to the family of hypotheses
involving ultra-rare SNV/indels which included a total of 74 tests
(Supplementary Table 5).
Confirmation of prior results: We first evaluated the prior WES
finding that schizophrenia cases have an excess of damaging
protein-coding URV (odds ratio [OR]= 1.07; 4877 cases and 6203
controls)10. As shown in Fig. 2, we found an excess of LOF
URVs in schizophrenia cases (OR= 1.082, P= 0.0002, BH-FDR
multiple-testing adjusted P= 0.0049). This excess was notable
(OR= 1.203, P= 0.0005, adjusted P= 0.0092) in genes that are
intolerant to LOF variation (defined as pLI > 0.9 in the non-
psychiatric subset of ExAC24, where pLI is the probability that a
gene is intolerant to a LOF mutation). Increased burden was
prominent in the subset of LOF-intolerant genes that are risk genes
from WES for neurodevelopmental disorders11 (OR= 2.983, P=
0.0011, adjusted P= 0.0163). A key advantage of WGS over WES
for protein-coding regions is independence of design, coverage,
and performance of exome capture baits16. The exome capture
baits used in WES are imperfect, however, after multiple testing
correction, we did not find any significantly increased burden of
coding URVs outside of targeted exonic sequences of LOF-
intolerant genes (Supplementary Fig. 9, Supplementary Table 5).
Burden analysis of noncoding ultra-rare SNV/indels in
constrained regions: We defined variants as putatively noncoding
if they did not alter sequence content of coding regions or splice
dinucleotides of GENCODE protein-coding transcripts. These
noncoding variants may confer risk via a variety of mechanisms
(e.g., by altering an unannotated protein-coding transcript,
untranslated regions, splicing, transcription factor binding, or
an epigenetic site). We evaluated burden of noncoding variants
that are more likely to be deleterious by focusing on ultra-rare
noncoding variants that are likely to be subject to purifying
selection in a manner similar to coding URVs. We compared
case/control burden of noncoding URVs across binned regions by
sequence constraint for the human species19 and by constraint
across mammalian species20 (Supplementary Fig. 10). The human
constraint was built upon the context-dependent tolerance score
(CDTS) which indicates the degree of depletion of genetic
variation at the population level using 11,257 human genomes
(the lower the percentile rank of CDTS the more constrained the
region)19. The mammalian constraint was based on genomic
evolutionary rate profiling (GERP) score which quantifies
substitution deficits in multiple alignments (the higher the GERP
score, the more constrained the region)20. We concentrated
subsequent noncoding URV analyses on variants in regions that
were highly constrained according to one of these two metrics
(CDTS < 1% or GERP ≥ 4) due to prior observation that the
overlap between CDTS (conservation in the current human
population) and GERP (interspecies conservation) was limited
and heavily enriched for protein-coding regions19. We did not
observe a case excess of noncoding URVs that survived multiple
test correction based on this criterion alone (OR= 1.009, P=
0.0342, adjusted P= 0.2819, Supplementary Fig. 10).
Burden in annotations experimentally derived from human
brain: Annotations from appropriate tissues help predict func-
tional variants7,28. We compared case/control burden of
noncoding URVs in constrained regions (as defined above
CDTS <1% or GERP ≥ 4) within functional annotations experim-
entally derived from human brain tissue known to effect gene
expression. These annotations include open chromatin regions
from ATAC-seq, frequently interacting regions (FIREs), topolo-
gically associating domains (TADs), and chromatin interactions
from Hi–C; epigenetic marks from ChIP-seq (CTCF, H3K27ac,
and H3K4me3). We also included annotations of brain-expressed
exons identified from long-read RNA-seq data29, as constrained
noncoding URVs inside brain exons could impact functional
noncoding elements within untranslated regions of annotated
transcripts or protein-coding sequences from unannotated
transcripts. We did not identify any single annotation with a
significant case excess of URVs within constrained regions
(Supplementary Fig. 11, Supplementary Table 5).
Burden in promoter regions: A recent study focused on de
novo SNV/indels found evidence for a contribution to autism
spectrum disorder from variants in constrained nucleotides
within promoter regions30. Defining promoter regions the same
way as in An et al.30 (2 kilobases (kb) upstream of an annotated
transcription start site), we compared case/control burden of
noncoding URVs within constrained nucleotides (as defined
above) in promoter regions of genes that are putatively
Fig. 2 Burden of coding ultra-rare SNVs and indels. X-axis: annotation
class. Y-axis: odds ratio. Legend: exomes: coding variants in all genes;
LOFtol: in genes tolerant to loss-of-function variation; LOFintol: in genes
intolerant to loss-of-function variation. For each specific burden test, we
used a vertical line to indicate the 95% confidence interval of odds ratio and
a dot at the center of the vertical line to indicate the point estimate of
odds ratio.
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LOF-intolerant (as defined above). No significant case excess was
observed (OR= 0.966, P= 0.9812, adjusted P= 0.9907). A
similar result was obtained when performing this test specifically
on the subset of LOF-intolerant genes previously described as
neurodevelopmental risk genes11 (OR= 0.99, P= 0.5551,
adjusted P= 0.6956). To take the three-dimensional genome into
account, we used brain chromatin interaction data to identify any
cis-regulatory elements (e.g. promoter and enhancers) connected
with LOF-intolerant genes. No significant case excess was
observed (OR= 1.006, P= 0.1904, adjusted P= 0.427).
X chromosome: We tested male cases and controls to
determine if the coding variant excess replicated in chrX genes.
We did not detect a significant difference in synonymous variant
burden or LOF variant burden but note that power was low.
Burden analysis of ultra-rare SVs. We performed analyses of
ultra-rare SVs on the full sample (1162 cases and 936 controls)
and on the subsample used for URV burden testing (1104 cases
and 921 controls). Note that cases with known pathogenic CNVs
or unusually high CNV burden were excluded18. Because all
results were similar, we report the analysis results using the full
sample. The total number of ultra-rare SVs in our sample was
6809 for DEL, 1917 for DUP, and 729 for INV. The sizes of these
ultra-rare SVs were smaller than those from SNP arrays (DEL
mean 15.2 kb for cases and 13.8 kb for controls; DUP mean 56.5
kb for cases and 52.6 kb for controls; and INV mean 100 kb for
cases and 76 kb for controls).
Confirmation of prior results: Higher genome-wide burden of
rare SVs in schizophrenia cases has been repeatedly observed in
studies using SNP arrays8,18 (i.e., rare, large SVs with MAF < 0.01
and size > 100 kb). Burden was greater for SVs that were deletions,
larger, or rarer. To calibrate our analyses, we verified this general
pattern of findings using WGS SV calls (Supplementary Table 6).
Genome-wide burden of ultra-rare SVs: Using the DEL, DUP,
and INV genotypes described above, we evaluated the genome-wide
burden of ultra-rare SVs (Supplementary Fig. 12 and Supplemen-
tary Table 7). We defined ultra-rare SVs as found once in the WGS
case/control cohort and absent from independent population
cohorts31,32. Consistent with previous reports8,18, ultra-rare DEL
were significantly enriched in cases (OR= 1.086, P= 0.0001, BH-
FDR multiple-testing adjusted P= 0.0029). The burden of ultra-
rare DUP and INV were similar between cases and controls (DUP:
OR= 1.06, P= 0.0920, adjusted P= 0.2052; INV: OR= 1.015, P=
0.2903, adjusted P= 0.4009). Most of these ultra-rare SVs were
noncoding (Supplementary Fig. 13, 87.2% for DEL, 71.1% for DUP,
and 89.4% for INV). When stratified by coding/noncoding status,
the results were similar (Supplementary Table 7).
Burden in epigenomic annotations from human brain: We
hypothesized that the elevated genome-wide burden of ultra-rare
SVs may be partitioned across functional elements with evidence
for gene regulation in the brain13. We focused on ultra-rare SVs
that intersected ≥10% of the functional elements (Fig. 3,
Supplementary Table 8). Burden tests found a significant
enrichment of ultra-rare SVs in schizophrenia cases that
impacted TAD boundaries from adult (OR= 1.613, P= 0.0037,
adjusted P= 0.0283) and fetal brain (OR= 1.581, P= 0.0039,
adjusted P= 0.0283). No significant enrichment was found for
any other class of functional elements. TAD boundaries have
been shown to be under purifying selection. Multiple studies
suggest that altering TAD boundaries results in the disarrange-
ment of enhancer and promoter contacts, thus impacting local
gene expression. Disruption of TAD boundaries by SVs have been
associated with developmental disorders33,34.
Burden in regulatory elements connected with schizophrenia
risk loci: We hypothesized that the elevated genome-wide burden
of ultra-rare SVs may be partitioning to regulatory elements
within schizophrenia risk loci. To take the three-dimensional
genome into account, we used chromatin interaction data from
adult brain to identify regulatory elements connected with
schizophrenia risk loci, capturing any empirically defined cis-
elements either nearby or distal13. As above, we performed a
burden test using the 10% overlap criterion for any ultra-rare
DEL, DUP, or INV in the regulatory elements of these
schizophrenia risk loci. No significant enrichment in schizo-
phrenia cases was found (Fig. 3, Supplementary Table 8).
Validation and analysis of ultra-rare TADs-affecting SVs. To
gain a deeper understanding, we followed up on the finding of
significantly increased burden of ultra-rare SVs that affected TAD
boundaries. We found that a higher rate of variants in cases versus
controls was present when those variants were stratified by coding
or non-coding status (Supplementary Fig. 14, Supplementary
Table 9) or by variant type (i.e., DEL, DUP, or INV; Supplementary
Fig. 15, Supplementary Table 10). Burden was greater for those
variants that were DEL, or had larger overlap with TAD boundaries.
Next, we attempted to verify the validity of those TADs-
affecting ultra-rare DEL and DUP that were detected in
schizophrenia cases. First, we looked up the GWA array data in
the same samples (Supplementary Table 11). We found that
27.9% of these DEL and 52.6% of these DUP were concordant
with GWA array data (50% reciprocal overlap) and were
additionally confirmed by inspecting their WGS read alignments
using IGV35 (Supplementary Figs. 16 and 17). The remaining
variants that were not found from GWA array data were notably
smaller in size (median 7.6 kb) than those concordant (median
181 kb), suggesting that they may have been missed by GWA
array technology. Second, for variants not verifiable using GWA
arrays, we manually inspected their WGS read alignments using
IGV35 (Supplementary Figs. 18 and 19), and all were confirmed.
Finally, we evaluated genomic features nearby those TADs-
affecting ultra-rare SVs that were detected in schizophrenia cases
(Supplementary Table 12). We found that these SVs span 4 – 995
kb and 71% of them (67 out of 94) overlapped ≥1 genes. There was
a notable difference between TADs-affecting ultra-rare DEL and
DUP: 44.7% (17 out of 38) of DUP overlapped genes had high pLI
scores or were genes implicated in schizophrenia or neurodevelop-
mental disorders, whereas 16.3% (7 out of 43) of DEL overlapped
genes had high pLI scores or were implicated in neurodevelop-
mental disorders (H0: no difference between DEL and DUP,
Fisher’s exact test P= 0.0072). Furthermore, 36.8% (14 out of 38) of
the DUP connected with 43 genes with high pLI scores or
implicated in neurodevelopmental disorders via a high-confidence
regulatory chromatin interaction (HCRCI); whereas 18.6% (8 out of
43) of the DEL connected with 18 genes with high pLI scores or
implicated in neurodevelopmental disorders via a HCRCI (Fisher’s
exact test P= 0.0824). Our observations are consistent with a
previous report that duplications display a more complex relation-
ship with chromatin features than deletions36. INV was similar to
DUP (Supplementary Table 12; H0: no difference between INV and
DUP, Fisher’s exact test P= 0.53).
Common variants with large effects were not identified.
Because SNP arrays do not cover the entire genome even with
imputation, we performed single-variant association analysis for
all common variants obtained from WGS. Given the sample size
of 2098 (1162 cases and 936 controls), we estimated that our
sample had ≥80% power to detect risk variants with MAF= 0.25
and genetic relative risks ≥2.0, assuming a type I error level of 5 ×
10−8 (Supplementary Fig. 6).
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SNV/indels: We analyzed 7,895,148 SNVs and 1,368,675 indels
with MAF > 0.01 for association with schizophrenia (Supple-
mentary Fig. 20). We obtained a λGC value of 1.03 and LD score
regression intercept of 0.997 (SE= 0.0065), indicating no
departure from null expectations or uncontrolled bias. Single-
variant association analysis was done using logistic regression
assuming an additive genetic model including PC2 as covariate
for autosomes, and sex and PC2 as covariate for chrX. A number
of variants exceeded genome-wide significance but, upon review,
all 15 were false positives due to lack of read alignment support.
These results are consistent with accumulated experience in
schizophrenia genomics where larger sample sizes are required to
detect common variant associations7. We believe that this null
result is important: we have excluded the possibility of common
variants (MAF > 0.01) with large effects in less accessible parts of
the genome that have not been evaluated by GWA SNP arrays.
SVs: Association analysis of common SVs has the potential to
identify causative mutations leading to actionable findings, and
much of this class of variants is inaccessible to SNP-based studies.
Here we performed association analysis for SVs with MAF > 0.01,
using logistic regression models and covariates as described above.
The main analysis was for 2199 common DEL (Supplementary
Fig. 21) but no association reached genome-wide significance. We
then inquired into common DUP, INV, ALU, LINE1, and SVA, but
also found no significant associations (Supplementary Figs. 22–26).
Heritability estimation using WGS. Heritability is the propor-
tion of phenotypic variance explained by genetic factors.
Understanding the sources of missing heritability for schizo-
phrenia – the discrepancy between pedigree-heritability of
60–65%3,4 and common-variant SNP-heritability of 24%6 – is
important for experimental designs to identify additional trait loci
and possibly for subsequent precision medicine initiatives. Using
WGS data for height and body mass index, Wainschtein et al.
recently found WGS-heritability very close to twin/pedigree
heritability14. WGS allowed them to include effects in genomic
regions of low MAF and low LD, precisely the regions that are
poorly captured by typical SNP arrays or imputation.
Following Wainschtein et al.’s approach14, we estimated
schizophrenia heritability from our WGS data using 1151 cases
and 911 controls (post-QC subjects and pairwise genetic
relatedness < 0.05), and 17,364,971 sequence variants (post-QC
autosomal SNV/indels observed ≥ 3 times or MAF ≥ 0.0007). To
evaluate the effect of progressive inclusion of more variants, we
computed heritability in different ways by selecting WGS variants
that corresponds to variant locations in HapMap337, those
imputable from 1000 G p3v522 and HRC r1.121, and finally by
including all WGS variants.
First, we assessed common SNP-heritability in the WGS
sample using the GREML single-component method implemen-
ted in GCTA38,39. Using 1,189,077 SNPs from WGS that
corresponds to the SNP locations in HapMap3, the SNP-
heritability was 0.45 (standard error [SE] 0.089, liability scale
assuming lifetime risk of 1%). Using 7,141,717 SNV/indels
from WGS that corresponds to the variant locations imputable
from 1000GP p3v5, the SNP-heritability was 0.48 (SE 0.091).
These estimates are numerically greater than that estimated
Fig. 3 Burden of ultra-rare SVs in brain epigenomic annotations and related analysis. For each specific burden test, we use a vertical line to indicate the
95% confidence interval of odds ratio and a dot at the center of the vertical line to indicate the point estimate of odds ratio. Labels on X-axis indicate the
specific annotations that were considered. “TADbou”: TAD boundaries. Epigenomic annotations include TADbou.AdultBrain, TADbou.FetalBrain,
ATACseq.AdultBrain, FIRE.AdultBrain, CTCF, H3K27ac, and H3K4me3. Regulatory elements connected with schizophrenia risk loci are labeled as “gene.
set.name_HiC.loops.int”. For example, “CELF4_ HiC.loops.int” means regulatory elements of the CELF4 gene set identified via chromatin interaction (a.k.a
HiC loops) data in human brain. Detailed information about gene sets considered can be found in Methods. Amongst the loci tested, only TAD boundaries
derived from both fetal and adult brain tissue showed a significant degree of evidence for excess in cases relative to controls.
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from SNP arrays in the full Swedish sample (5001 cases;
GCTA SNP-heritability using HapMap3 data: 0.32, SE 0.03, and
using 1000 Genomes data: 0.33, SE 0.03)6, presumably due to
the fact that more stringent evidence of schizophrenia was used
for samples selected for WGS than that in the full sample
(Methods).
Next, we evaluated SNP-heritability using 8,498,854 SNV/
indels from WGS that corresponds to the variant locations
imputable from HRC r1.1. We used the recommended GREML-
LDMS method in GCTA39,40 because it is unbiased regardless the
properties (e.g. MAF and LD) of the underlying causal variants
(Supplementary Fig. 27a). The estimated SNP-heritability was
0.52 (SE 0.22).
Finally, we used all sequence variants (17,364,971 as above)
from WGS and the GREML-LDMS method39,40 to estimate
WGS-heritability and partition additive genetic variance. We
found the estimated WGS-heritability was 0.56 (SE 0.51). The
point estimate of 0.56 is closer to pedigree-heritability (0.6–0.65,
refs. 3,4), but the SE is large. For rare variants with MAF
0.0007–0.01, WGS variants in the low-LD group contributed to
0.40 of the phenotypic variance whereas variants in the high-LD
group contributed to 0.01 of the variance (Supplementary
Fig. 27b). In contrast, for HRC-imputable variants, 0.06 and
0.03 of the phenotypic variance was contributed by variants in the
low- and high-LD groups for MAF 0.0007–0.01 (Supplementary
Fig. 27a). The contribution to phenotypic variance from rare
variants in low-LD with nearby variants was only revealed by
WGS. These variants could only be directly assayed by WGS as
they are not present in SNP arrays and their imputation is not
accurate14.
In sum, the point estimates for heritability were progressively
larger as we included more variants and there was a sizable
contribution from rare variants with low-LD metrics that are
accessible only via WGS. However, our estimates of SNP- and
WGS-heritability had large standard errors. This was due to
limited sample size and case-control study design (i.e. not
continuous trait as height or body mass). The WGS-heritability
estimate had the largest SE which was additionally due to the
large number of rare variants with low MAF and low LD. The
sampling variance of SNP-based heritability estimate is approxi-
mately inversely proportional to sample size and is proportional
to the effective number of independent variants41,42 Furthermore,
we likely underestimated WGS-heritability, especially the con-
tribution from rare variants with MAF < 0.001: First, Wainschtein
et al.14 was able to include WGS variants with MAF as low as
0.0001 (corresponding to MAC ≥ 3 in TOPMed data with 21K
subjects), whereas in this study we were limited to a minimum
MAF of 0.0007 (corresponding to MAC ≥ 3 in 2K subjects).
Second, based on a simulation using AbCD43 assuming 2062 EUR
individuals and 30x WGS, we have >99% power to detect variants
at MAF > 0.001 but only >53% power to detect variants for MAF
0–0.001. The lowest MAF bin (MAF 0.0007–0.001) that we were
able to consider in this study likely included only half of the
variants that could have been observed in a sample with
10,000 subjects.
We believe it notable that, although not conclusive, our results
for schizophrenia are consistent with those of Wainschtein et al.
for height and body mass14,16. These results imply that, with
larger schizophrenia samples (e.g. a sample size of >33,000 is
needed to obtain an SE of 0.02, refs. 14,41,42), WGS data may be
able to fully recover the total additive genetic variance with
desired precision and will allow further partitioning of the
genome to finer MAF/LD groups as well as a variety of functional
annotations14,42. The still missing heritability of schizophrenia
may be only misplaced, in precisely the blind spots of SNP arrays
as has been anticipated for over a decade44.
Discussion
We have generated and analyzed a collection of WGS data for a
set of patients ascertained for schizophrenia that to our knowl-
edge is the largest described in a publication. The high depth and
uniformity of coverage across the genome for these case data
allowed us to detect the large majority of genetic variation that are
present in the genome, including SNVs, indels, CNVs, mobile
element insertions, and inversions. In addition, the availability of
similar WGS data from Swedish controls allowed us to system-
atically measure the burden of these different classes of variation
in a case/control manner.
Through the analysis of these data, we were able to replicate key
prior reported excess in schizophrenia of LOF URVs in genes that
are putatively LOF-intolerant as well as excess of rare deletions
genome-wide. This means that we can be more confident that the
load of such variants, while modest compared to the identified
contribution of common variation to schizophrenia risk, are a
subset of the total schizophrenia genetic risk architecture.
Our finding that ultra-rare SVs in schizophrenia cases are
enriched at TAD boundaries is not surprising. These variants
seem to confer a level of relative risk comparable to protein-
coding variants for which we have replicated an excess in schi-
zophrenia. These regions have been reported as being depleted of
deletions in human populations relative to the rest of the non-
coding genome36, and clear phenotypic consequences associated
with deletion of these elements have already been demonstrated
in a number of other diseases34. TAD boundaries are critical to
the formation and maintenance of chromatin structure13. The
disruption of these boundaries has the potential to rearrange
spatial orientation of regulatory elements that are needed for
proper expression, as well as lead to the formation of entirely new
TADs. Functional examples of such effects have already been
described in mouse models for limb malformation33. Based on
these prior observations it is unsurprising that of all noncoding
loci, the burden of these SVs appears to be highest relative to
controls in TAD boundaries.
While our data support an excess of TAD-affecting ultra-rare
SVs in schizophrenia cases relative to controls, the precise impact
of these variants on gene expression and regulation has yet to be
determined. Many of these SVs overlapped genes including some
of the risk genes for neuropsychiatric disorders. Mechanistic stu-
dies are needed to clarify the precise genomic consequences of
these TADs-affecting SVs in human brain. A possible future
investigation would be to work with patient derived cells with these
TADs-affecting SVs that we have identified and figure out what
promoter-enhancer pairing looks like, and if there are any potential
changes in gene expression. Our study has highlighted a specific
hypothesis for future functional analyses. It will be critical to
determine the precise functional effects of these variants on biol-
ogy, which, in a manner similar to common variant risk, are likely
to converge on higher order architectures of gene regulation7.
We chose not to analyze rare mobile element insertions
because variant calling for these variants appear to be noisy from
our 30× WGS and there was a lack of external dataset or analytic
approach for the need of quality control. Increased somatic L1
insertions have been recently reported in neurons of schizo-
phrenia patients using postmortem brain tissues45. The detection
of somatic L1 insertions required very deep WGS (e.g. 200×) and
tailored analytic methods (e.g. machine learning45). For similar
reasons, we also chose not to evaluate translocations and complex
SVs in this study as we feel that these variants can be better
detected from WGS using long-insert jumping libraries, deeper
coverage, and targeted capture of breakpoints46.
The analysis of noncoding variants from WGS data is challen-
ging due to the sheer volume of the noncoding genome and lim-
ited methods to predict functional changes28,30,46. Recently the
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category-wise association study (CWAS) framework has been
developed and applied to WGS studies of autism spectrum dis-
order using 7608 samples from 1902 families28,30,46. The CWAS
approach applies multiple annotation methods to define tens of
thousands of annotation categories each of which are tested for
association and accounted for multiple testing. However, there is a
trade-off between false positives and false negatives. In this study
we adopted the spirit of the CWAS approach and focused on
empirically determined annotation methods including (1) con-
servations of DNA sequence that were estimated from cataloging
and comparing genetic variation across human and mammalian
species19,20, (2) multiple epigenomic annotations that were
experimentally generated from human brain12,13, (3) genes and
regions that were empirically associated with psychiatric disorders.
This approach combined with the relative homogeneity of the
Swedish sample helped improve the power to identify functional
variants while controlling for false discovery rate.
We failed to detect an excess of risk variation beyond a couple
of specific classes of variation, and we believe that this is largely
due to a lack of power. Prior data has demonstrated that power to
implicate common variation with schizophrenia risk is only suf-
ficient with a much larger case/control cohort, on the order of
Ncase/control >10,0003,6. This also applies to implication of genomic
loci based on ultra-rare variation. Cohorts larger than ours have
failed to implicate burden of ultra-rare coding variants in indi-
vidual genes with schizophrenia risk10, and implication of SVs
with schizophrenia at locus level resolution required cohorts far
larger than ours8. Since we can assume that noncoding ultra-rare
SNVs and indels will have a smaller relative risk conferred than
damaging coding variants, it is clear that implication of this class
of variation both across the genome and at locus level resolution
will also require a far larger cohort size. Furthermore, larger
samples will be necessary to ensure findings are replicable30.
In sum, to effectively identify the subset of rare variation across
the genome that confers schizophrenia risk in patients, we will need
to follow the blueprint constructed for common variant GWAS.
Substantial collaborative effort will be critical. WGS is expensive
and generates a large quantity of sequence data that are difficult to
efficiently store and analyze en masse. The financial and compu-
tational burden inherent to a case/control WGS analysis with
sufficient power for discovery is too much for individual groups or
institutions, and will only be feasible through collaborative work in
meta-analyzing case/control WGS datasets. The WGS data we have
generated are meant to be included in these future efforts.
Methods
Ethics. We have complied with all relevant ethical regulations. The study protocol
and all procedures on data from human research subjects were approved by the
appropriate ethical committees in Sweden and the US (University of North Car-
olina [Institutional Review Boards], Karolinska Institutet [Regionala Etik-
prövningsnämnden, Stockholm], University of Uppsala [Regionala
Etikprövningsnämnden, Uppsala]). All participants gave their written informed
consent. All genomic coordinates are given in NCBI Build 37/UCSC hg19.
Subjects. All schizophrenia cases included this study are from the Swedish Schi-
zophrenia Study (S3). Detailed descriptions of S3 procedures are available else-
where17 and are briefly summarized here. S3 cases were identified via the Swedish
Hospital Discharge Register that captures >99% of all inpatient hospitalizations in
Sweden47.The register is complete from 1987 and augmented by psychiatric data
from 1973 to 1986. The sampling frame is thus population-based and covers all
hospital-treated patients. The Hospital Discharge Register contains dates and ICD
discharge diagnoses for each hospitalization, and captures the clinical diagnosis
made by attending physicians. Case inclusion criteria: ≥2 hospitalizations with a
discharge diagnosis of schizophrenia or schizoaffective disorder, both parents born
in Scandinavia, and age ≥18 years. Case exclusion criteria: hospital register diagnosis
of any medical or psychiatric disorder mitigating a confident diagnosis of schizo-
phrenia as determined by expert review, and included removal of 3.4% of eligible
cases due to the primacy of another psychiatric disorder (0.9%) or a general medical
condition (0.3%) or uncertainties in the Hospital Discharge Register (e.g., contiguous
admissions with brief total duration, 2.2%). The validity of this case definition of
schizophrenia is strongly supported as described in17. Ethical committees in Sweden
and in the US approved all procedures and all subjects provided written informed
consent (or legal guardian consent and subject assent). We also obtained permis-
sions from the area health board to which potential subjects were registered.
Potential cases were contacted directly via an introductory letter followed by a
telephone call. If they agreed, a research nurse met them at a psychiatric treatment
facility or in their home, obtained written informed consent, obtained a blood
sample, and conducted a brief interview about other medical conditions in a lifetime.
The S3 included more than 5000 schizophrenia cases, from which we selected
1165 cases for whole-genome sequencing (WGS) in the current study. Our main
goal in selection was typical Swedish ancestry and clear schizophrenia caseness.
Cases carrying known pathogenic copy number variants (CNVs) (e.g. 22q11del,
16p11dup) were not selected as a primary question of this study is to evaluate the
contribution of novel loci on schizophrenia risk. DNA was extracted from
peripheral blood samples. Specifically, our selection procedures required the
following case inclusion criteria to be met: (1) have high-quality/sufficient DNA
that satisfied all criteria: concentration ≥ 80 µg/ml, volume ≥ 150 µl, and purity
ratio 1.7–2.2; (2) used in GWA study17; (3) have typical Swedish ancestry defined
by the first two PCs used in17; (4) do not carry known large pathogenic CNVs and
are not outliers for total number of CNVs as identified in Szatkiewicz et al.18; (5)
have stringent evidence of schizophrenia that satisfied all criteria: >8 inpatient or
outpatient psychiatric treatment contacts for schizophrenia or schizoaffective
disorder, ≥30 inpatient days for schizophrenia, ≥5 redeemed prescriptions for
antipsychotics, and few or no treatment contacts for bipolar disorder. Institutional
Review Boards at University of North Carolina and regional ethics committee at
Karolinska Insitutet (Regionala Etikprövningsnämnden, Stockholm) approved all
study procedures and all subjects provided written informed consent.
All control subjects included this study are from the SweGen project, a
population-based high-quality genetic variant dataset for the Swedish population.
One of the aims of SweGen is to enable WGS association studies for national
patient cohorts studies in Sweden, by providing data on well-matched national
controls selected on the basis of the genetic structure of the Swedish population.
Detailed description of the SweGen subjects are available elsewhere48 and are
briefly summarized here. SweGen project included a total 1000 individuals, of
which 942 individuals were selected from The Swedish Twin Registry (STR)49 and
58 from The Northern Swedish Population Health Study (NSPHS)50. Both STR
and NSPHS are population-based collections and were approved by local ethics
committees. STR is a national registry of Swedish born twins established in the
1960s and, at present, holds information on 85,000 twin pairs. In total, 11,000
individuals from the STR (one per monozygous twin pairs) participated in
TwinGene and had existing SNP array genotyping. The Twingene study is a
nation-wide and population-based study of Swedish born twins agreeing to
participate. The TwinGene sample collection represents the Swedish geographic
population density distribution. Based on principal component analysis (PCA), 942
unrelated individuals were selected from TwinGene participants for whole-genome
sequencing, mirroring the density distribution. All participants gave their written
informed consent and the TwinGene study was approved by the regional ethics
committee (Regionala Etikprövningsnämnden, Stockholm, dnr 2007-644-31, dnr
2014/521-32). NSPHS is a health survey in the northern Swedish country of
Norrbotten. Based on PCA, 58 individuals were selected from NSPHS. The NSPHS
study was approved by the local ethics committee at the University of Uppsala
(Regionala Etikprövningsnämnden, Uppsala, 2005:325 and 2016-03-09). All
participants gave their written informed consent to the study including the
examination of environmental and genetic causes of disease in compliance with the
Declaration of Helsinki. Given the selected 1000 subjects that constitutes SweGen, a
PCA using genotypes from high-density SNP arrays was performed and confirmed
that the SweGen control cohort captured the diversity in the country. Furthermore,
since STR and NSPHS are already established national sample collections that do
not reflect recent migration patterns, the SweGen control cohort is likely to reflect
the genetic structure of Swedish individuals that have been present in Sweden for at
least one generation.
From the SweGen subjects, we selected the 942 STR/TwinGene individuals as
controls in this study because of their matched ancestry with selected schizophrenia
cases. Phenotype data was not allowed in the SweGen project in order to make a
less restrictive access policy possible. Consequently, we were unable to screen for
the presence of individuals with schizophrenia. However, we estimate that at most
1 control individual may carry a schizophrenia diagnosis (given the estimated
schizophrenia prevalence of 0.0009 in the full STR/TwinGene project of 11,000
individuals). Misclassification of a single control subject will not likely affect the
results or the power of the study. DNA for the STR/TwinGene individuals was
extracted from blood.
All S3 subjects, including those in this WGS study, had GWA SNP array
genotyping17 and exome sequencing9,10. DNA was extracted from peripheral
venous blood for all subjects. GWAS array genotyping was done in six batches at
the Broad Institute of MIT and Harvard using Affymetrix 5.0 (3.9%), Affymetrix
6.0 (38.6%), and Illumina OmniExpress (57.4%). Exome sequencing was done at
the Broad Institute of MIT and Harvard in twelve separate waves. The first wave
used Agilent SureSelect Human All Exon Kit and Illumina GAII. Other waves used
a newer version Agilent SureSelect Human All Exon v.2 Kit and Illumina HiSeq
2000 and HiSeq 2500 instruments. Paired-end reads of 76 bp were used across all
waves. Analyses of SNP array and exome sequencing data are previously published.
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Data on common SNPs is published in Ripke et al.17. Data on exonic SNVs and
indels is published in Genovese et al.10. Data on large rare CNVs are published in
Szatkiewicz et al.18. All data are in NCBI build 37/UCSC hg19 coordinates.
Whole-genome sequencing and data processing. Library preparation and
sequencing was performed by the National Genomics Infrastructure platform in
Sweden. All cases and controls were processed using identical library preparation
and sequencing protocols at two facilities. WGS libraries were prepared from ~1 μg
DNA using Illumina TruSeq PCR-free DNA sample preparation kits targeting an
insert size of 350 bp. Library preparation was performed according to the manu-
facturer’s instructions. The protocols were automated using an Agilent NGS
workstation and Beckman Coulter Biomek FXp. WGS clustering was done using
cBot, and paired-end sequencing with 150 bp read length was performed on Illumina
HiSeqX (HiSeq Control Software 3.3.39/RTA 2.7.1) with v2.5 sequencing chemistry.
Identical analysis pipelines (including software tool versions) were used for
processing all case and control samples together. For alignment, the workflow
engine Piper51 (v1.4.0) was used to perform pre-processing and variant discovery,
coordinated using the National Genomics Infrastructure pipeline framework.
Following the GATK guidelines, raw reads were aligned to the GRCh37 human
reference genome (human_g1k_v37.fasta) using bwa mem52 (v0.7.12). The
resulting alignments (.BAM) were sorted and indexed using SAMtools53 (v0.1.19).
Alignment quality control statistics were gathered using qualimap54 (v2.2).
Alignments for the same sample from different flowcells and lanes were merged
using Picard MergeSamFiles (v1.120, https://broadinstitute.github.io/picard).
For quality control of aligned sequence reads, we ran FastQC55 on the BAM-
files in order to understand sequencing quality and to identify outlier samples
which might be subject to contamination. We analyzed a number of sequencing
QC metrics (e.g., adapter content, per base N nucleotide content, per base sequence
content, per base sequence quality, per sequence GC content, per sequence quality
scores, sequence duplication level, and sequence length distribution). We analyzed
a number of sequence coverage QC metrics produced by SAMtools flagstat (e.g.,
sequencing depth, percentage of mapped reads, percentage of properly paired
reads, percentage of singletons, percentage of duplicates, and percentage of paired
end reads with one mate mapped to a different chromosome). Finally, we checked
uniformness of read coverage using BEDTools genomecov56, based on which we
required that samples with good coverage have ≥80% of bases be covered at least
20× for confident variant calling. These procedures identified one outlier sample (a
schizophrenia case).
We confirmed the identity of all subjects by comparing SNP genotypes from
WGS to those from GWA SNP array genotyping17 and exome sequencing10.
Identity-by-decent was estimated using PLINK57 (v1.9) for each sample between
WGS-based genotypes and array- or WES-genotypes in overlapping SNPs. Based
on this analysis, identity was confirmed for all samples (i.e. no sample swap was
found). The identity of SweGen subjects have been confirmed previously in48.
Variant discovery and genotyping - SNV and indels. We processed all case and
control BAM files together and performed joint genotyping of SNVs and indels
across all samples using GATK (v3.3)58.
The raw alignments were then processed following GATK best practices with
GATK (v3.3). Alignments were realigned around indels using GATK
RealignerTargetCreator and IndelRealigner, duplicate marked using Picard
MarkDuplicates (v1.120), and base quality scores were recalibrated using GATK
BaseRecalibrator. Finally, gVCF files were created for each sample using the GATK
HaplotypeCaller (v3.3). Reference files from the GATK v2.8 resource bundle were
used throughout. All these steps were coordinated using Piper (v1.4.0).
Joint genotyping was conducted on all cases and controls as recommended by
GATK58. Due to the large number of samples, 22 batches of 100 samples were
merged into 22 separate gVCF files using GATK CombineGVCFs. The 22
individual gVCF files were split by chromosome and further combined with
CombineGVCFs. As a result, a single gvcf file was obtained which was used as
input for GATK GenotypeGVCF. Subsequently, SNVs and indels were extracted
from the resulting gVCF files. To further select high-quality genetic variants,
GATK VQSR filtering was executed on SNPs and indels separately using GATK
VariantRecalibrator and ApplyRecalibration walkers. VQSR sensitivity thresholds
were selected based on maximization of sensitivity of variant discovery in
comparison with WES data previously performed on the same samples.
GATK Variant Quality Score Recalibration (VQSR) was used to filter variants
as recommended by GATK guidelines. The SNV VQSR model was trained using
SNP sites from HapMap3.337, 1000 Genomes Project (1000GP) sites found to be
polymorphic on Illumina Omni 2.5 M SNP arrays59, 1000GP Phase 1 high-
confidence SNPs60, and dbSNP61 (v138). A 99.6% sensitivity threshold was applied
to filter variants resulting in a Ti/Tv ratio of 2.001. The indel VQSR model was
trained using high-confidence indel sites from62, 1000GP and dbSNP (v138) and a
99.0% sensitivity threshold was used. The sensitivity thresholds were determined
empirically by comparing to WES data in the same samples to optimize sensitivity
and specificity of variant detection. We kept only the ‘PASS’ variants based on
results of VQSR.
Variant calling on sex chromosomes was performed separately from the
autosomes. GATK Haplotype Caller walker was executed with ploidy= 1 flag on
male samples except for PAR regions which were done with ploidy= 2.
CombineGVCFs and GenotypeGVCFs were performed by analogy with the
processing of the autosomes, see above. VQSR filtering was performed with the
sensitivity thresholds inferred from the autosomes. To assess the robustness of the
callset, we evaluated hard filters in comparison to VQSR filter. We constructed
histograms of 16 variant quality metrics reported by GATK GenotypeGVCFs,
manually selected reasonable thresholds for good quality variants, and performed
hard filtering according to the selected thresholds. We found that these two
filtering strategies, VQSR and hard filtering, gave nearly identical results
confirming robustness of the final variant call set.
Variant discovery and genotyping—structural variants. We applied three
complimentary algorithms for the discovery and genotyping of structural variants
(SVs). These algorithms were chosen for their established performance in the
1000GP32. We processed all case and control genomes together using protocols
recommended by specific algorithms.
We used ExpansionHunter63 (v2.5.5) with default parameters to identify
expansions of short tandem repeats. Using PCR-free WGS, ExpansionHunter can
accurately genotype known pathogenic repeat expansions even when the expanded
repeat is larger than the read length. With ExpansionHunter v2.5.5, the catalog of
known pathogenic repeat expansions covers repeats in 16 genes: AR, ATN1,
ATXN1, ATXN10, ATXN2, ATXN3, ATXN7, C9ORF72, CACNA1A, CSTB, DMPK,
FMR1, FXN, HTT, JPH3, and PPP2R2B. The sizes of the pathogenic repeat
expansions are documented in the literature (Table S3). Using the disease
thresholds, we identified pathogenic repeat expansions, and the number of cases
and the number of controls carrying these pathogenic repeat expansions.
We used Delly64 (v0.7.7) with default parameters to detect and genotype three
types of SV call sets: deletions, tandem duplications, and inversions that are
between 500 bp and 500Mb. We ran the default protocol for germline DNA and
high-coverage sequencing. Specifically, for each type of SV, we (1) discover SV sites
per sample using paired-end mapping signature and split-read refinement; (2)
merge SV sites into a unified site list following strategies used by 1000GP32 (i.e., for
deletions and duplications: 70% reciprocal overlap and a max. breakpoint offset of
250 bp; for inversions: 90% reciprocal overlap and a max. breakpoint offset of 50
bp); (3) genotype the unified SV sites in all samples; (4) merge all genotyped
samples to get a single VCF; and (5) apply the default germline SV filters to identify
confident SVs (i.e., min. fractional ALT support= 0.2, min. SV size= 500 bp, max.
SV size= 500Mb, min. fraction of genotyped samples= 0.75, min. median GQ for
carriers and non-carriers= 15, max. read-depth ratio of carrier vs. non-carrier for a
deletion= 0.8, min. read-depth ratio of carrier vs. non-carrier for a duplication=
1.2, and “PASS” variants). Finally, we kept only high-confident genotypes that
passed the per-sample genotype filter (i.e., FORMAT/FT= PASS), and had
additional support from read-depth-based copy number estimates (i.e., FORMAT/
CN < 2 for deletions, CN > 2 for duplications, and CN= 2 for inversion
genotypes).
We used the Mobile Element Locator Tool (MELT, v2)65 to detect and genotype
three types of mobile element insertions (MEI) including ALU, SVA, and LINE1.
We used the MELT-SPLIT workflow with default parameters which consists four
steps: (1) MEI discovery in individual samples; (2) group analysis whereby
discovery information are merged across all samples to build models containing all
available evidence for each candidate MEI site; (3) genotyping all WGS samples
using the merged MEI discovery information; (4) final filtering and merging of
individual samples into final VCF. We used the default filters (no-call filter, 5′ and
3′ evidence filter, discordant pair overlap filter, low complexity filter, and allele
count 0 filter) and included in the final VCF only those variants that passed the
default filtering of MELT.
Evaluation of variant detection. For SNV/indels, we used variant calls from
exome sequencing to evaluate genotype accuracy from WGS. We focused on the
autosomes and estimated genotype accuracy by calculating the concordance rate
between WGS-based genotypes and those obtained from exome sequencing across
variants that overlapped between the two technologies. We calculated the overall
concordance rate as well as concordance rates when WES-based genotypes are
homozygous reference, heterozygous, and homozygous non-reference. In all cal-
culations, only genotypes with sequencing depth ≥ 10 and GQ ≥ 20 were included
in the comparison. Python code “concordance.py” (https://github.com/
jinszatkiewicz/swsczwgs) was used for this analysis.
For deletions and duplications, we evaluated concordance using prior data from
GWA SNP array or exome sequencing. Previously GWA genotyping arrays
detected large and rare deletions and duplications genome-wide and WES detected
rare exonic deletions and duplications in the same samples. We compared the
concordance between WGS-based genotypes with those based on either GWAS
array or exome sequencing across overlapping variants. Any overlapping variants
must have ≥50% reciprocal overlap and occur in the same individual. We
calculated the overall concordance rate as well as concordance rates when
genotypes from the GWA array or exome sequencing are heterozygous and
homozygous non-reference. Variant overlap was performed using BEDTools
(v2.28.0).
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Quality control. For subject quality control, we used PLINK (v1.9). In sum, subject
QC excluded 9 subjects for failed sequencing quality metrics (1 case excluded), sex
mismatch (1 control excluded), sex chromosomal abnormality (2 cases with XXY
excluded), and one of any pair of subjects with high relatedness π^ > 0:2 (5 controls
excluded). These procedures resulted in a final sample size of 2098 subjects
(1162 schizophrenia cases and 936 controls), all of whom had SNV/indel missing
rate per sample < 0.01 and heterozygosity rate < 0.1. In selection of the schizo-
phrenia cases, we excluded carriers of known large pathogenic CNVs and abnor-
mally high total number of CNVs as identified by Szatkiewicz et al.18 using SNP
arrays. We confirmed this fact using SV calls from WGS.
Sex check was performed using heterozygosity rate of sex chromosomes and by
examining the coverage of sex chromosomes. This identified a sex mismatch when
the reported sex does not match the biological sex and chromosomal abnormality
when extra chromosomes were present. Relatedness testing and principal
component analysis (PCA) were done following established pipelines using eligible
bi-allelic autosomal SNPs using PLINK (v1.9). Of all bi-allelic autosomal SNPs, we
removed variants that had minor allele frequency < 0.05, missing rate per variant
>0.01, missing rate per variant in cases and controls >0.02 or P < 0.005,
Hardy–Weinberg equilibrium false discovery rate (FDR) < 1×10−6 (controls) or
<1×10−10 (cases), or were in linkage disequilibrium (r2 > 0.05). Relatedness testing
identified any pairs of subjects with π^ > 0:2, based on which we removed one
member of each relative pair. PCA estimated 20 PCs which were used in empirical
evaluation of covariates to be included in association analyses. Furthermore, for
quality control purpose, we performed PCA of our data together with 1000
Genomes Project data on HapMap individuals and SweGen data on NSPHS
individuals. The same quality steps were followed for the identification of eligible
SNPs in the combined data.
For SNV/indel quality control, we removed variants if missing rate per variant >
0.01 (before sample removal) and applied genotype QC by setting low quality
genotypes with DP < 10 or GQ < 20 as missing. We then removed variants that
were: monomorphic, missing rate per variant > 0.02 (after genotype QC and
sample removal), missing rate per variant difference in cases and controls >0.02 or
P < 0.005, Hardy–Weinberg equilibrium FDR < 1×10−6 (controls) or <1×10−10
(cases). After QC, we extracted variants with minor allele frequency (MAF) ≥ 0.01
for common variant association analysis and the remaining for rare variant
aggregated association analysis. These QC procedures were done using PLINK
(v1.9).
For SV quality control, we followed established pipelines8. SVs were removed if
they overlapped by more than 66% with large genome gaps (e.g., centromeres),
segmental duplications, or regions subject to somatic V(D)J recombination in white
blood cells, with the logic that these variant calls are likely artifactual. Finally, we
extracted variants with MAF ≥ 0.01 for common variant association analysis and
the remaining for rare variant aggregated association analysis. These QC
procedures were done using PLINK (v1.07).
Annotation of variants. We used VEP66 (v91), vcfanno67 (v0.2.9), and AnnotSV68
(v1.1.1) for variant annotations.
For population allele frequency annotations, we annotated SNV/indels using
population allele frequencies from gnomAD r2.0.2 genomes and ExAC r0.3 non-
psych exomes24,25. For SVs, we annotated the variants using population allele
frequencies from 1000GP and Database of Genomic Variants (DGV)31,32. We used
the default settings in AnnotSV, i.e. a SV from 1000GP or DGV is reported if an
overlap of >70% is found with a SV to annotate.
For sequence constraints in humans, we annotated variants using the context-
dependent tolerance score (CDTS) using the map of sequence constraint for the
human species19. Files containing CDTS were downloaded from http://www.hli-
opendata.com/noncoding/. The downloaded CDTS scores were presented in 10 bp
bins in hg38, which was liftover to GRh37/hg19 for the analyses in this study.
When a variant spans multiple CDTS bins, mean CDTS was computed and used to
annotate the variant. For sequence constraints in mammals, we used the genomic
evolutionary rate profiling (GERP) score20.
For transcript-level annotations, we annotated variants with VEP (v91) using
Ensembl transcripts from GENCODE69 (v16). For SNVs/indels, we further
annotated the variants using annotation database dbNSFP 3.5_a. Exonic SNV/
indels are classified into groups following criteria based on those used in
Genovese et al.10: synonymous, missense non-damaging, missense damaging
(dbNSFP_MetaSVM_pred= “D” and dbNSFP_fathmm_MKL_coding_pred= “D”),
and loss-of-function (stop-gain, frameshift, or splice donor/acceptor).
For brain exons annotations, we obtained a dataset of long-read RNAseq data
from a published dataset of long-read RNA sequencing of human brain tissue29.
The data came in the form of a BED file where each interval represents a uniquely
observed exonic region in the data, along with the total number of reads aligning to
the region. We took the subset of exons with at least 10 overlapping reads,
sufficient support for the exon coming from an isoform that is unlikely to be mere
transcriptional noise. We split exons into (1) those within coding loci, and (2) those
outside coding loci by simply subsetting intervals on gene-based merged translation
start/stop intervals, representing a space where a novel coding exon could
potentially be found.
For brain epigenomics annotations, we relied on empirically generated
annotations that have shown to be important to gene regulation in the brain.
Epigenomic data are restricted to the autosomes. First, we used the open chromatin
regions obtained from ATAC-seq on adult prefrontal cortex brain samples as
reported in Bryois et al.12. ATAC-seq was performed on adult prefrontal cortex
brain samples from 135 individuals with schizophrenia and 137 controls. A total of
118,152 high-confidence ATAC-seq peaks were identified. Second, we used the
“easy-HiC” readouts obtained from adult temporal cortex as described in Giusti-
Rodríguez et al.13. “Easy Hi–C” was applied to six postmortem samples (N= 3
adult temporal cortex and N= 3 fetal cerebra) and 1.323 billion high-confidence
cis-contacts were used for analyses. Three major read-outs were generated
including frequently interacting regions (FIREs), chromatin interactions (a.k.a.
Hi–C loops), and topologically associating domains (TADs). FIREs were defined as
40-kb genomic bins with significantly more Hi–C interactions (FIRE score P <
0.05). Chromatin interactions were defined as intra-chromosomal chromatin
interactions between 10 kb bins that were >20 kb apart (i.e., not contiguous) and
≤2Mb apart. FIREs are a small subset of all chromatin interactions, which have
considerably more three-dimensional contacts. Chromatin interactions have a
strong tendency to occur within TADs (discrete megabase-scale regions with less
frequent interactions outside the regions). TAD boundaries are defined in 40 kb
bins. Finally, we further included epigenetic marks (i.e. CTCF, H3K27ac, and
H3K4me3) obtained from ChIP-seq using postmortem brain tissue from fetal and
adult samples that were generated in13.
Using gene model defined by GENCODE (v16), we assessed gene sets
previously implicated in schizophrenia and neurodevelopmental disorders
including:
● Loss-of-function (LOF) intolerant genes: we used genes from Lek et al.24.
● Calcium Channel gene set: we used the 26 genes from voltage-dependent
calcium channel, available at https://www.genenames.org/cgi-bin/genefamilies/
set/253.
● CELF4 gene set: we used genes with “iCLIP occupancy” >0.2 from
Supplementary Table 4 of Wagnon et al.70.
● CHD8 gene set: we used genes from Cotney et al.71.
● FMRP Darnell gene set: we used the 842 mouse genes from Supplementary
Table 2A of Darnell et al.72, including all genes with FDR < 0.01.
● NMDARC: we used a list of combined NMDAR and ARC complexes genes
from Supplementary Table 9 of Kirov et al.73.
● PSD gene set: we used a gene list generated from human cortex biopsy data
from Bayes et al.74.
● PSD-95 gene set: we used a gene list generated from human cortex biopsy data
from Bayes et al.74.
● RBFOX gene sets: we selected RBFOX1/2/3 genes from Supplementary Table 1
of Weyn-Vanhentenryck et al.75.
● Genes.ID/DD/ASD: we selected 288 genes implicated in de novo variant studies
from Supplementary Tables 15–18 of Nguyen et al.11, based on q-value < 0.05
for developmental delay (DD), q-value < 0.1 for autism spectrum disorder
(ASD), q-value < 0.1 for intellectual disability (ID), and q-value < 0.5 for
epilepsy (EPI).
● SCZGWAS: genes implicated in schizophrenia common variant association
studies, for which we used genes from the 145 regions known to be associated
with schizophrenia from Pardinas et al.6.
● CMCqval05: The CommonMind Consortium (CMC) sequenced RNA from
dorsolateral prefrontal cortex of schizophrenia cases (N= 258) and control
subjects (N= 279), from which we selected genes implicated to have
differential expression in human brain between cases and controls based on
q-value < 0.0576.
For certain tests of SNV/indel burden we focused on burden within gene
regions of a generalized coding transcript structure, broadly defined as 35 kb
upstream of the most distal transcription start site to 10 kb downstream of the most
distal transcription start site (transcript_35kb_10kb).
Variant subsetting. Protein coding sequences are defined using protein-coding
transcripts from GENCODE (v16). We focused coding SNV/indel analyses on a set
of variants which to a high degree of confidence impact bases involved in the
production of a functional protein. Coding variants have an at least one transcript-
level IMPACT classification of LOW, MODERATE or HIGH according to VEP
(v91). We defined noncoding SNV/indels if they did not alter sequence content of
coding regions or splice dinucleotides of GENCODE protein-coding transcripts.
Noncoding variants only have IMPACT classifications of MODIFIER according to
VEP (91).
For SVs, we followed criteria used in Brandler et al.77 to define coding versus
noncoding variants. Protein coding sequences are defined using the consensus
coding sequence from GENCODE (v16). Coding deletions, duplications, or mobile
element insertions are defined as those affecting any protein-coding sequences.
Coding inversions are either having one or both breakpoints inside a protein-
coding exon of a gene, or having breakpoints in two different introns of a gene and
overlapped with at least one coding exon, or having one breakpoint in an intron of
a gene and the other breakpoint outside of that gene. Inversions that inverted an
entire gene or genes but had intergenic breakpoints were considered noncoding.
From the post-QC variant callsets, we defined ultra-rare SNV/indels as
being a singleton within our WGS cases/control cohort (allele count= 1 in the
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2098 post-QC subjects) and absent from independent population cohorts
(gnomAD genomes allele count= 0 and non-psychiatric subset of ExAC allele
count= 0)24,25. This is because the full ExAC and gnomAD exome cohort include
exome sequence data derived from schizophrenia case samples included in this
study, and applying any MAF constraints using the full cohorts could bias
association analysis results against schizophrenia cases. Subsetting of noncoding
ultra-rare SNV/Indels on annotations was done using in-house python scripts,
VCFscreen v0.1 (https://github.com/Halvee/VCFScreen), based on interval overlap
with annotations defined by genomic coordinates.
From the post-QC SV callset, we defined ultra-rare SVs as being single
occurrence in our case/control cohort (allele count= 1 in the 2098 post-QC
subjects), as well as being absent in independent population cohorts including
1000GP and DGV31,32. Based on the default setting of AnnotSV68, a SV was absent
in population cohorts if it did not overlap or overlapped <30% of any variant in the
population databases. Subsetting of ultra-rare SVs on annotations was done using
PLINK (v1.07) based on interval overlap.
Power calculation and correction for multiple comparisons. We used the R/gap
package (v1.2.1, https://github.com/jinghuazhao/R) to estimate statistical power for
association analyses. We assumed an additive model, lifetime risk of schizophrenia
of 1%, and two type I error levels: (1) 5 × 10−8 as an established genome-wide
significance threshold for single-variant association, (2) 1 × 10−5 as in Werling
et al.46. We computed the minimal detectable genotypic risk ratio to achieve 20%,
80% power over a range of frequency of risk alleles in the population. For single-
variant association test, the X-axis of the power plot represents the frequency of a
single variant. For burden test, the X-axis of the power plots represents the
aggregated frequency of a set of variants aggregated for a target region of interest.
To correct for multiple comparisons in the analysis of common variant
association, we used the established genome-wide significance threshold of 5 ×
10−8. To correct for multiple comparisons in burden analyses of ultra-rare variants,
we applied the Benjamini and Hochberg false discovery rate (BH-FDR) method to
the family of hypotheses involving ultra-rare SNV/indels which included a total of
74 tests summarized in Supplementary Table 5, and to those involving ultra-rare
SVs which included a total of 29 tests summarized in Supplementary Tables 7 and
8. We used the p.adjust function in R (v3.2.2., https://www.r-project.org) to
implement the BH-FDR method. We used a threshold of 0.05 on the FDR adjusted
P values (a.k.a. q values) to consider statistical significance.
Burden of ultra-rare SNV/Indels. Given that the large majority of ultra-rare
SNVs and indels (URVs) are not assumed to confer risk in schizophrenia cases, we
first tested the null that the total rate of these variants is not a significant predictor
of schizophrenia status. Before outlier pruning, with 1162 cases and 936 controls,
we fitted a simple logistic regression model with case/control status as the
dependent variable and count per sample of URVs as the predictor variable. We
found that cases had a higher mean URV count (4456 vs. 4289, P= 0.002, two-
sided), and that this was primarily driven by the presence of a portion of samples
with unusually high URV counts. The URV outlier samples may be biasing the
analysis of URVs even though they were not a concern for the analysis of common
variants and SV, and will need to be removed. Following an approach previously
established in the full Swedish sample10, we pruned samples that had an outlier
total URV count, here defined as >6000 (Supplementary Fig. 7). The outlier
samples appeared to have relatively higher ancestry heterogeneity (Supplementary
Fig. 8) similar to the previous finding from the full Swedish sample in Genovese
et al.10. After outlier pruning, we had 1104 cases and 921 controls and there was no
evidence for a difference in mean URV count between cases and controls after this
pruning step was carried out (4262 vs 4249, P= 0.4225, one-sided assuming higher
burden in cases).
Burden testing was done using VCFscreen (v0.1) and R (v3.2.2). All tests of
URV burden in cases relative to controls were carried out using a logistic regression
model framework that has been utilized in prior studies10. Specifically, the
dependent outcome variable in logistic regression is phenotype (schizophrenia= 1,
control= 0). The primary predictor is the count per sample of URVs that are
specific to target region annotation, whether coding or noncoding. And, based on
empirical evaluation, we included three covariate variables in logistic regression:
mean_coverage, PC2 (the only PC of the 20 PCs determined from common SNPs
which predicted sample case/control status at P < 0.01), and total URV count per
sample. We carried out one-sided statistical tests assuming increased burden of
URV in cases. Logistic regression models were implemented by the glm function in
R (v3.2.2). Odds ratios were computed to measure the increase in the likelihood of
having disease per unit increase in URV burden. Empirical P-values were derived
by 10,000 permutations by swapping phenotype labels.
Burden of ultra-rare SVs. Analysis was done using PLINK (v1.07) and R (v3.2.2).
All tests of ultra-rare variant burden in cases relative to controls were carried out
using a logistic regression framework that has been established in prior studies8,18.
Analysis was done for each type of variants separately. In order to ensure the
robustness of the analysis, we first empirically evaluated variables that could
potential confound association results. We fit a multiple linear regression model,
where dependent/outcome variable was the genome-wide total number of ultra-
rare SVs, and the independent/predictor variables were sex, mean sequence cov-
erage, and the first three principal components derived from common SNP gen-
otypes. Only the first principal component (PC1) showed significant association
with genome-wide burden of ultra-rare SVs. To control its potential confounding
effect, we included PC1 as covariate in all tests of burdens of ultra-rare SVs.
For genome-wide burden tests, we fit the following logistic regression model:
y ~ covariate+ global, where y is the outcome phenotype variable (schizophrenia= 1,
control= 0), covariate is the empirically determined covariate variable (i.e. PC1), and
global is the genome-wide total number of ultra-rare SVs. For burden tests in target
regions, we fit the following logistic regression model for each target region: y ~
covariate+ global+ target_region, where target_region is the count per sample of
ultra-rare SVs that are specific to the target region annotation. Variables global and
target_region are computed based on input variants (i.e. coding, noncoding, or
combined coding and noncoding). We carried out one-sided statistical tests assuming
increased burden of ultra-rare SVs in cases. Logistic regression models were
implemented by the glm function in R (v3.2.2). Odds ratios were computed to
measure the increase in the likelihood of having disease per unit increase in the
burden of ultra-rare SVs. Empirical P values were derived by 10,000 permutations by
swapping phenotype labels.
Single-variant association analysis. Analysis was done using PLINK (v1.9). Fol-
lowing the general guideline for logistic regression, we used a MAF cutoff of 0.01 to
ensure that there were at least 10 events in the less frequent category. Post-QC
variants that had MAF > 0.01 were subject for single-variant association analysis.
Established variant filters were used to ensure all variants had missing rate per var-
iant < 0.02, missing rate per variant difference in cases and controls < 0.02 (P > 0.005),
and Hardy–Weinberg equilibrium FDR< 1 × 10−6 (controls) or <1 × 10−10 (cases).
To empirically determine confounding factors, we fit logistic regression models
where the dependent outcome variable is phenotype (case/control status) and the
independent predictor variables are sex and the first 20 PCs determined from
common SNPs. Only PC2 showed significant association with phenotype.
Therefore, we included PC2 as covariate for the analysis of autosomal variants, and
included PC2 and sex as covariates for the analysis of chromosome X.
A logistic regression model with additive genetic model (Plink –logistic) with
empirically determined covariates was used to estimate association between single
variants and schizophrenia. Statistical tests were two-sided. The established threshold
of 5 × 10−8 was used to identify genome-wide significance. Following association, we
used IGV to inspect read alignments underlying each putative variant that exceeded
the genome-wide significance threshold. False positives that had no IGV support were
excluded. Manhattan plots were constructed using R (v3.2.2).
Analysis was done separately for SNV/indels, deletions, duplications, inversions,
ALU, SVA, and LINE1. For SNV/indels, deletions, duplications, and inversions, we
filtered variants as described above. For ALU, LINE1, and SVA, we additionally
restricted our attention to the most reliable variants by selecting variants with a
quality score of 5 (best). For ALU, MAF was set to be >0.05 and Hardy–Weinberg
equilibrium threshold to FDR < 0.05 for both cases and controls.
Heritability estimation. Following Wainschtein et al.14, we started with the initial
set of QC-passing subjects and post-QC SNV/indels and additionally required that
each variant observed at least three times in our dataset (i.e. MAF starts at 0.0007).
Next we further removed one of each pair of individuals with estimated genetic
relatedness >0.05. These procedures resulted in 1151 cases and 911 controls and
17,364,971 sequence variants to be used for narrow-sense heritability estimation.
HapMap3 SNPs were downloaded from the HapMap ftp site. To identify imputable
variants from Haplotype Reference Consortium (HRC)21 and 1000 Genomes
Project Consortium (1000GP)22, we used previously imputed data obtained by
using SNP genotypes of the schizophrenia subjects from Illumina OmniExpress
array genotyping and imputing the array genotype data to the HRC.r1.1 or the
1000GP p3v5 reference panel using EAGLE278 (v2.0.5). On the HRC imputation
variants, we excluded variants with Imputation Score Info <0.8, individual missing
rate >0.05, genotype missing rate >0.05, MAF < 0.0001 and P-value <1e-06 of
Hardy–Weinberg equilibrium test. On the 1000GP imputation variants, we
excluded variants with Imputation Score Info <0.8, and allele frequencies <0.005 or
allele frequencies >0.995 based on previous results17.
Heritability analysis was done using GCTA39 (v1.26.0, v1.92.3beta). We
assumed lifetime risk of schizophrenia of 1%. We calculated principal components
from 1,189,077 HapMap337 SNPs selected from the WGS data and included the
first 10 PCs (calculated from the same set of HapMap3 SNPs) for the analyses
conducted using GCTA’s GREML-LDMS40. To test the robustness of the estimates,
we repeated the analysis while correcting for the first 4 PCs, and for the first 12 PCs
and found the results were similar.
With the GREML-LDMS approach, a total of 14 MAF and LD bins were
considered and the same set of bins were used for both the imputed-SNPs and for
the WGS sequence variants. Specifically, we split the variants into seven different
bins based on MAF (0.0007–0.0001, 0.001–0.01, 0.01–0.1, 0.1–0.2, 0.2–0.3, 0.3–0.4,
0.4–0.5) and for each bin of variants, computed SNP-based LD scores with the
following parameters: –ld-score-region 200, -ld-wind 10000, ld-rsq-cutoff 0. For a
given bin of variants defined by MAF, we defined low LD as < median LD score,
and high LD as ≥median LD score. For each bin subsetted on MAF (and further
split by LD), we used GCTA to produce a genetic relationship matrix (GRM) from
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the set of genotypes. We then used the REML function (via the Fisher scoring
algorithm, as implemented in GCTA via –reml-alg 1) to conduct a GREML-LDMS
analysis.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Summary statistics from single-variant association analysis in this study can be
downloaded from Psychiatric Genomics Consortium’s website at https://www.med.unc.
edu/pgc/download-results/causal-variants-within-scz/. All other summary statistics and
supporting data are available in Supplementary Information. Due to recent changes in
Swedish and European Union regulations regarding genetic data, we are unable to
deposit individual-level data into controlled-access repositories like dbGaP. Collaborative
analyses are possible and can be pursued by contacting the authors.
Code availability
Analysis software used in this study include the following: HiSeq Control Software
3.3.39/RTA 2.7.1; Piper (v1.4.0, https://doi.org/10.5281/zenodo.154586); bwa (v0.7.12,
http://bio-bwa.sourceforge.net/); SAMtools (v0.1.19, http://samtools.sourceforge.net/);
Picard (v1.120, https://broadinstitute.github.io/picard/); qualimap (v2.2, http://qualimap.
bioinfo.cipf.es/); FastQC (v0.11.4, https://www.bioinformatics.babraham.ac.uk/projects/
fastqc/); BEDTools (v2.28.0, https://bedtools.readthedocs.io/en/latest/); GATK (v3.3,
https://software.broadinstitute.org/gatk/); PLINK (v1.9, https://www.cog-genomics.org/
plink/1.9/); PLINK (v1.07, http://zzz.bwh.harvard.edu/plink/); ExpansionHunter (v2.5.5,
https://github.com/Illumina/ExpansionHunter); Delly (v0.7.7, https://github.com/
dellytools/delly); MELT (v2, http://melt.igs.umaryland.edu/manual.php); VEP (v91,
https://github.com/Ensembl/ensembl-vep); vcfanno (v0.2.9, https://github.com/brentp/
vcfanno); AnnotSV (v1.1.1, https://lbgi.fr/AnnotSV/); VCFscreen (v0.1, https://github.
com/Halvee/VCFScreen); R (v3.2.2., https://www.r-project.org); R/gap package (https://
github.com/jinghuazhao/R); GCTA (v1.26.0, v1.92.3beta, https://cnsgenomics.com/
software/gcta/#Overview); JMP (v11, https://www.jmp.com/); AbCD Calculator (https://
yunliweb.its.unc.edu/abcd_web/AbCD.php). Python code “concordance.py” and other
relevant codes are posted at https://github.com/jinszatkiewicz/swsczwgs.
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